Product Code: VMR11210077
Value Market Research deeply researched the Global CAR T Cell Therapy Market to foresee a significant growth in the industry over the upcoming years. The global car t cell therapy market report provides a complete industry analysis, market size, market share, growth trends, and forecasts for 2023 to 2028. The report starts with a detailed market introduction and an executive summary that highlights the report's key growth numbers. The subsequent chapters discuss the value chain of the market, Porter's Five Forces Model, and market attractiveness analysis. An exclusive chapter on COVID-19 impact analysis has been added to understand how the market has responded to the pandemic.
The market dynamics section of the report elaborates the current market drivers, restraints along with the challenges/risks and upcoming opportunities. This section can be of high interest for any company's strategists and new product development department. The global car t cell therapy market study segments the market and provides the market size in terms of revenue and/ or sales. This data is bifurcated by region and later by countries. The data is collected through detailed primary interviews and industry experts across the world. The detailed methodology can be seen in our sample reports. These market estimates are also influenced by the latest social, political and economic changes along with the current market dynamics that are affecting this car t cell therapy market.
The next sections of the car t cell therapy market report studies the market competitiveness and profiles some key market players/manufacturers. These sections are knowledgeable for understanding the competitor's product-line, their financials, recent developments and the top market share owners in the industry.
Countries Covered in the report are as below:
- North America: United States, Canada, and Mexico
- Europe: United Kingdom, Germany, France, Italy, Russia, Spain & Rest of Europe
- Asia-Pacific: China, India, Japan, South Korea, Australia & Rest of APAC
- Latin America: Brazil, Argentina, Peru, Chile & Rest of Latin America
- Middle East and Africa: Saudi Arabia, UAE, Israel, South Africa
Market Segmentation in the report is as below:
By Target Antigen
- CD 19
- CD 20
- CD 138
- GD2
- CD22
- CD30
- CD33
- HER1
- HER2
- Others
By Therapeutic Application
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma
- Acute Myeloid Leukemia
- Multiple Myeloma
- Pancreatic Cancer
- Neuroblasta
- Breast Cancer
- Hepatocellular
- Carcinoma
- Colorectal Cancer
- Others
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . CAR T CELL THERAPY - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 By Target Antigen
- 3.7.2 By Therapeutic Application
- 3.7.3 By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
- 5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
- 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
- 5.3. Market: Pre V/S Post COVID-19
- 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
- 5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY TARGET ANTIGEN
- 6.1 Overview by Target Antigen
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Target Antigen
- 6.4 CD 19 Market by Regions
- 6.6 CD 20 Market by Regions
- 6.5 CD 138 Market by Regions
- 6.7 GD2 Market by Regions
- 6.8 CD22 Market by Regions
- 6.9 CD30 Market by Regions
- 6.10. CD33 Market by Regions
- 6.11 HER1 Market by Regions
- 6.12 HER2 Market by Regions
- 6.13 Others Market by Regions
7 . GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY THERAPEUTIC APPLICATION
- 7.1 Overview by Therapeutic Application
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Therapeutic Application
- 7.4 Acute Lymphocytic Leukemia Market by Regions
- 7.5 Chronic Lymphocytic Leukemia Market by Regions
- 7.6 Diffuse Large B-Cell Lymphoma Market by Regions
- 7.7 Acute Myeloid Leukemia Market by Regions
- 7.8 Multiple Myeloma Market by Regions
- 7.9 Pancreatic Cancer Market by Regions
- 7.10. Neuroblasta Market by Regions
- 7.11 Breast Cancer Market by Regions
- 7.12 Hepatocellular Market by Regions
- 7.13 Carcinoma Market by Regions
- 7.14 Colorectal Cancer Market by Regions
8 . GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America
- 8.3.1. Overview, Historic and Forecast Data
- 8.3.2. North America By Segment
- 8.3.3. North America By Country
- 8.3.4. United State
- 8.3.5. Canada
- 8.3.6. Mexico
- 8.4. Europe
- 8.4.1. Overview, Historic and Forecast Data
- 8.4.2. Europe by Segment
- 8.4.3. Europe by Country
- 8.4.4. United Kingdom
- 8.4.5. France
- 8.4.6. Germany
- 8.4.7. Italy
- 8.4.8. Russia
- 8.4.9. Rest Of Europe
- 8.5. Asia Pacific
- 8.5.1. Overview, Historic and Forecast Data
- 8.5.2. Asia Pacific by Segment
- 8.5.3. Asia Pacific by Country
- 8.5.4. China
- 8.5.5. India
- 8.5.6. Japan
- 8.5.7. South Korea
- 8.5.8. Australia
- 8.5.9. Rest Of Asia Pacific
- 8.6. Latin America
- 8.6.1. Overview, Historic and Forecast Data
- 8.6.2. Latin America by Segment
- 8.6.3. Latin America by Country
- 8.6.4. Brazil
- 8.6.5. Argentina
- 8.6.6. Peru
- 8.6.7. Chile
- 8.6.8. Rest of Latin America
- 8.7. Middle East & Africa
- 8.7.1. Overview, Historic and Forecast Data
- 8.7.2. Middle East & Africa by Segment
- 8.7.3. Middle East & Africa by Country
- 8.7.4. Saudi Arabia
- 8.7.5. UAE
- 8.7.6. Israel
- 8.7.7. South Africa
- 8.7.8. Rest Of Middle East And Africa
9 . COMPETITIVE LANDSCAPE OF THE CAR T CELL THERAPY COMPANIES
- 9.1. Car T Cell Therapy Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10 . COMPANY PROFILES OF CAR T CELL THERAPY INDUSTRY
- 10.1. Company Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Novartis International AG
- 10.3.1. Company Overview
- 10.3.2. Financials
- 10.3.3. Products
- 10.3.4. Recent Developments
- 10.4. Kite Pharma, Inc.
- 10.4.1. Company Overview
- 10.4.2. Financials
- 10.4.3. Products
- 10.4.4. Recent Developments
- 10.5. Juno Therapeutics
- 10.5.1. Company Overview
- 10.5.2. Financials
- 10.5.3. Products
- 10.5.4. Recent Developments
- 10.6. Bluebird Bio, Inc.
- 10.6.1. Company Overview
- 10.6.2. Financials
- 10.6.3. Products
- 10.6.4. Recent Developments
- 10.7. Sorrento Therapeutics Inc.
- 10.7.1. Company Overview
- 10.7.2. Financials
- 10.7.3. Products
- 10.7.4. Recent Developments
- 10.8. Mustang Bio, Inc.
- 10.8.1. Company Overview
- 10.8.2. Financials
- 10.8.3. Products
- 10.8.4. Recent Developments
- 10.9. Aurora Biopharma Inc.
- 10.9.1. Company Overview
- 10.9.2. Financials
- 10.9.3. Products
- 10.9.4. Recent Developments
- 10.10. Legend Biotech, Pfizer, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financials
- 10.10.3. Products
- 10.10.4. Recent Developments
- 10.11. CARsgen Therapeutics, Ltd.
- 10.11.1. Company Overview
- 10.11.2. Financials
- 10.11.3. Products
- 10.11.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies